

# **OMI** Antibody

Catalog # ASC10245

## **Product Information**

**Application** WB, IF, E, IHC-P

Primary Accession <u>043464</u>

**Other Accession** <u>AAB94569</u>, <u>5870865</u>

Reactivity
Human
Rabbit
Clonality
Polyclonal
Isotype
IgG
Calculated MW
Concentration (mg/ml)
Conjugate
Human
Rabbit
Rabbit
Polyclonal
IgG
Unconjugate

**Application Notes**OMI antibody can be used for detection of OMI by Western blot at 0.5 to 1

□g/mL. Antibody can also be used for immunohistochemistry starting at 10

□g/mL. For immunofluorescence start at 20 □g/mL.

## **Additional Information**

**Gene ID** 27429

Other Names OMI Antibody: OMI, PARK13, PRSS25, OMI, Serine protease HTRA2,

mitochondrial, High temperature requirement protein A2, HtrA2, HtrA serine

peptidase 2

Target/Specificity HTRA2;

**Reconstitution & Storage** OMI antibody can be stored at 4°C for three months and -20°C, stable for up

to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high

temperatures.

**Precautions** OMI Antibody is for research use only and not for use in diagnostic or

therapeutic procedures.

#### **Protein Information**

Name HTRA2

**Synonyms** OMI, PRSS25

**Function** [Isoform 1]: Serine protease that shows proteolytic activity against a

non-specific substrate beta-casein (PubMed: <u>10873535</u>). Promotes apoptosis by either relieving the inhibition of BIRC proteins on caspases, leading to an

increase in caspase activity; or by a BIRC inhibition-independent,

caspase-independent and serine protease activity-dependent mechanism (PubMed: 15200957). Cleaves BIRC6 and relieves its inhibition on CASP3,

CASP7 and CASP9, but it is also prone to inhibition by BIRC6

(PubMed:36758104, PubMed:36758105). Cleaves THAP5 and promotes its

degradation during apoptosis (PubMed: 19502560).

**Cellular Location** Mitochondrion intermembrane space. Mitochondrion membrane; Single-pass

membrane protein Note=Predominantly present in the intermembrane space.
Released into the cytosol following apoptotic stimuli, such as UV treatment,

and stimulation of mitochondria with caspase-8 truncated BID/tBID

**Tissue Location** [Isoform 1]: Ubiquitously expressed.

## **Background**

OMI Antibody: Inhibitor of apoptosis proteins (IAPs) were initially identified in baculoviruses as proteins that inhibit apoptosis of the host cells to allow time for viral replication. Cellular homologues containing at least one baculoviral IAP repeat (BIR) motif essential for their anti-apoptosis activity have been identified in yeasts and higher organisms and often act by binding and inhibiting processed caspases. The activity of these proteins can be modulated by the expression of proteins such as Smac/DIABLO and XAF-1 which displace or prevent the binding of caspases by IAPs. Recently, a mitochondrial serine protease termed Omi/HtrA2 has been found to bind IAPs. Similar to Smac, Omi possesses a conserved IAP-binding motif, but acts to cleave IAPs to irreversibly inactivate IAPs and promote apoptosis.

#### References


Crook NE, Clem RJ, and Miller LK. An apoptosis inhibiting baculovirus gene with a zinc finger like motif. J. Virol. 1993; 67:2168-2174.

Liston P, Fong WG, and Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22:8568-80.


Vaux DL and Silke J. Mammalian mitochondrial IAP binding proteins. Biochem. Biophys. Res. Comm. 2003; 304:499-504.

Suzuki Y, Imai Y, Nakayama H, et al. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell 2001; 8:613-21.


# **Images**



Western blot analysis of OMI in human colon cell lysates with OMI antibody at (A) 0.5 and (B) 1 µg/mL.



Immunohistochemistry of OMI in human colon tissue with OMI antibody at 10 µg/mL.



Immunofluorescence of OMI in human colon tissue with OMI antibody at 20  $\mu\text{g/mL}.$ 

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.